Radius Health, Inc. (RDUS) Position Boosted by Rhumbline Advisers
Rhumbline Advisers boosted its position in Radius Health, Inc. (NASDAQ:RDUS) by 9.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,480 shares of the biopharmaceutical company’s stock after buying an additional 3,740 shares during the period. Rhumbline Advisers owned approximately 0.10% of Radius Health worth $1,921,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new position in Radius Health in the first quarter valued at $105,000. Sei Investments Co. increased its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 46 shares in the last quarter. Karp Capital Management Corp bought a new stake in Radius Health in the first quarter valued at $217,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Radius Health in the first quarter valued at $228,000.
Shares of Radius Health, Inc. (RDUS) opened at 33.54 on Friday. Radius Health, Inc. has a 1-year low of $31.58 and a 1-year high of $59.22. The firm has a 50-day moving average of $37.32 and a 200 day moving average of $39.12. The company’s market capitalization is $1.46 billion.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period last year, the company posted ($1.01) earnings per share. On average, equities research analysts expect that Radius Health, Inc. will post ($5.58) earnings per share for the current year.
Several equities research analysts have weighed in on RDUS shares. Jefferies Group LLC set a $34.00 price target on shares of Radius Health and gave the company a “hold” rating in a research note on Monday, June 5th. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, May 22nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $53.60.
In related news, CFO Jose Carmona bought 3,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was purchased at an average cost of $32.83 per share, with a total value of $98,490.00. Following the transaction, the chief financial officer now owns 3,000 shares in the company, valued at approximately $98,490. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech bought 150,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 469,100 shares of company stock valued at $16,328,382. Corporate insiders own 15.00% of the company’s stock.
Radius Health Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.